Pfizer Accupril Recall: FDA Class II

Why it was recalled

CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

Product description

Accupril (Quinapril HCl Tablets) 20 mg, 90 Tablets, Rx only NDC 0071-0532-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017

Lot numbers, UPCs & expiration codes

Lots: DX8682 Exp. MAR 31 2023; DG1188 Exp. MAR 31 2022

Where it was sold

Nationwide and Puerto Rico

What to do if you have this product

Compare the lot number and expiration date on your package with the codes above.
Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
If you have symptoms you think are related, contact your doctor. In an emergency call 911.
Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number: D-0873-2022
Classification: Class II
Status: Terminated
Recall initiated: Apr 22, 2022
FDA report date: May 25, 2022
Quantity: 10,304 bottles
Recall type: Voluntary: Firm initiated
Recalling firm: Pfizer Inc.

Original FDA data

Every field from FDA enforcement report D-0873-2022, exactly as published.

Show all FDA fields

City: New York
State: NY
Status: Terminated
Country: United States
Event ID: 90064
Address: 235 East 42nd Street
Code information: Lots: DX8682 Exp. MAR 31 2023; DG1188 Exp. MAR 31 2022
Postal code: 10017-5703
Report date: May 25, 2022
Product type: Drugs
Recall number: D-0873-2022
Classification: Class II
Recalling firm: Pfizer Inc.
Product quantity: 10,304 bottles
Termination date: Oct 5, 2023
Reason for recall: CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
Voluntary / mandated: Voluntary: Firm initiated
Product description: Accupril (Quinapril HCl Tablets) 20 mg, 90 Tablets, Rx only NDC 0071-0532-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017
Distribution pattern: Nationwide and Puerto Rico
Recall initiation date: Apr 22, 2022
Initial firm notification: Press Release
Center classification date: May 16, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0873-2022, published May 25, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: Oct 2, 2026. Content last changed: Oct 2, 2026.

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

Pfizer Accupril Recall

Summary